Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 1st ADC Kadcyla Approved for HER2-Positive Breast Cancer: Chugai
September 25, 2013
- Unique Marketing System Jacks Up Profits at Vital KSK; Customer-by-Customer Cost Analyses Lend Support
September 24, 2013
- Sanwa Kagaku, DSP to Terminate Copromotion Deal for Seibule
September 24, 2013
- Sanofi K.K. Launches GLP-1 Receptor Agonist Lyxumia
September 20, 2013
- Eisai’s US Unit to Collaborate with Polish Research Firm Selvita on Anticancer Agents
September 20, 2013
- MTPC Completes Acquisition of Medicago, Now Ready to Bolster Vaccine Development
September 20, 2013
- Ethical Drug Sales Up 5.7% in July: Crecon Report
September 20, 2013
- Daiichi Sankyo, Mitsubishi UFJ Capital Establish New Fund to Support Ventures in Japan
September 19, 2013
- Eslicarbazepine Monotherapy Meets Primary Endpoint in PIII Trials: DSP
September 19, 2013
- GSK to Return All Rights to EPO Biosimilar to JCR Pharmaceuticals
September 19, 2013
- Kyowa Kirin Aims for 10% Share in a Highly Competitive Market for Diabetes Treatments, but Onglyza’s Chances of Success Remain in Doubt
September 19, 2013
- Demand Growing for Transdermal Patches in Graying Japan, Drug Makers Gear Up for Development
September 18, 2013
- Otsuka’s Samsca Wins Add’l Indication for Fluid Retention in Liver Cirrhosis Patients; World’s 1st Such Approval
September 18, 2013
- Takeda Grants Arbor Exclusive Rights for Edarbi Family of Products in US
September 17, 2013
- Xalkori Significantly Extends PFS in Japanese Patients: Pfizer
September 17, 2013
- Chugai Launches Breast Cancer Drug Parjeta
September 13, 2013
- Eisai Launches Halaven in Russia, First Product to Be Marketed by Company
September 13, 2013
- Hisamitsu Initiates PII Study of Transdermal Ropinirole for RLS Treatment in Japan
September 13, 2013
- Generic Drug Market Shows Steady Growth in 1st Quarter; Eisai, Meiji Seika Pharma Report Sharpest Growth in Sales
September 13, 2013
- Taiho’s TS-1 Failed to Significantly Improve Survival of Patients in Second-Line Treatment
September 12, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…